Merck & Co. reported median five-year follow-up results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 study evaluating its partnership with Moderna on intismeran autogene combined with Keytruda in high-risk stage III/IV melanoma patients. The combination reduced the risk of recurrence or death by 49% versus Keytruda monotherapy, matching the benefit seen at three years. Safety data remained consistent with prior analyses. Merck and Moderna plan to present comprehensive primary and secondary endpoint data at an upcoming medical conference. With an estimated 112,000 new melanoma cases in the U.S. in 2026, Jefferies projects potential peak sales in the multi-billion-dollar range if Phase 3 trials confirm these durable results.

Merck has entered a $30 million collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop an updated, more affordable version of its existing Ebola vaccine for low- and middle-income countries. The effort will focus on reformulating the vaccine for easier distribution, reducing cold-chain requirements and production costs. CEPI will contribute $20 million, with Merck funding the remaining $10 million. The updated vaccine is expected to enter preclinical testing in the second half of 2026 and, if successful, advance to Phase 1 trials by early 2027, supporting WHO goals for epidemic preparedness in sub-Saharan Africa and other high-risk regions.

Merck’s Gardasil franchise continues to face challenging market conditions, particularly in China and Japan, where a sharp sales decline has persisted through the fourth quarter of 2025. Internal forecasts suggest quarterly revenues for the human papillomavirus vaccine could remain under pressure into the first half of 2026. Management has outlined cost-containment measures and accelerated development of next-generation formulations, targeting regulatory submissions in 2027. Investors will be watching Merck’s Q4 earnings call for updated guidance on Gardasil and potential mitigation strategies for sustained revenue growth.

Beyond its established oncology and vaccine businesses, Merck is advancing a diversified pipeline that now includes eight ongoing Phase 2 and Phase 3 trials of mRNA-based therapies in collaboration with Moderna and other partners. These studies span melanoma, non-small cell lung cancer, renal cell carcinoma, muscle-invasive bladder cancer and metastatic squamous NSCLC. Analysts at Morningstar and William Blair have highlighted the long-term revenue potential if Merck can replicate its Phase 2b melanoma results across additional tumor types, estimating a multi-billion-dollar expansion opportunity for its mRNA platform by the end of the decade.